ARTV vs ASMB

Artiva Biotherapeutics, Inc. vs Assembly Biosciences, Inc. — Valuation Comparison 2026

ARTV

Biotechnology
Artiva Biotherapeutics, Inc.
Quality
4.9
out of 10
Value Trap
20
SAFE
Price
$7.61
Last close
Models
9/13
Active
VS

ASMB

Biotechnology
Assembly Biosciences, Inc.
Quality
6.1
out of 10
Value Trap
18
SAFE
Price
$27.73
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType ARTV Fair ValueARTV Upside ASMB Fair ValueASMB Upside
Bayesian DCF Intrinsic $2.17 -71.5% $6.31 -77.3%
First Chicago Scenario $0.43 -94.6% $5.49 -80.2%
ML-RIV Intrinsic $1.32 -82.6% $3.04 -89.0%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ARTV vs ASMB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ARTV vs ASMB — Which Stock Is More Undervalued?

ASMB scores higher with a 6.1/10 quality rating vs ARTV's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Artiva Biotherapeutics, Inc. (ARTV) and Assembly Biosciences, Inc. (ASMB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ARTV currently trades at $7.61 with a QOC of 4.9/10, while ASMB trades at $27.73 with a QOC of 6.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).